Morgan Stanley’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Morgan Stanley’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-388,302	Closed	-$24.1M	–	8066
2023 Q4	$24.1M	Buy	388,302 +377,007	+3,338%	+$9.37M	﹤0.01%	3161
2023 Q3	$251K	Buy	+11,295	New	+$237K	﹤0.01%	5479

Morgan Stanley's RYZB Position: Q1 2024 in Review

Morgan Stanley sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 388,302 shares — an estimated $24.1M sold.

Morgan Stanley first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $24.1M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

Morgan Stanley reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 388,302 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $24.1M.
Morgan Stanley first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Morgan Stanley's RayzeBio, Inc. Common Stock position peaked at $24.1M in Q4 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.